Javascript must be enabled to continue!
A combination of 2 rapid immunoassays significantly improves diagnostic sensitivity for heparin-induced thrombocytopenia
View through CrossRef
Abstract
Objectives
To evaluate the diagnostic performance of chemiluminescent immunoassay (CLIA), latex immunoturbidimetric assay (LIA), and the combination of CLIA/LIA with respect to the functional heparin-induced platelet aggregation (HIPA) test.
Methods
An observational retrospective study was conducted on 100 patients. All samples were initially tested with CLIA on the ACL TOP AcuStar, and then we performed LIA and CLIA tests concurrently (on the same samples on the ACL TOP 970 CL) and the HIPA test.
Results
The CLIA test was performed on both the AcuStar and the ACL TOP 970 CL, and results were concordant: 68% of patients were negative, and 32% were positive. The HIPA test confirmed a diagnosis in 26 of 32 and identified 6 false-positive patients and 1 false-negative patient. The LIA test was performed on the ACL TOP 970 CL: 64% of patients were negative, and the remaining 36% were positive. The HIPA test confirmed a diagnosis in 24 patients and identified 12 false-positive and 3 false-negative patients. The combination of CLIA and LIA tests allowed us to categorize 27 true-positive, 13 false-positive, 0 false-negative, and 60 true-negative patients.
Conclusions
The combination of CLIA/LIA provides high sensitivity with a progressively greater probability of detecting platelet-activating antibodies with a higher assay reactivity, reaching 100% when both automated assays yield moderate or strong results.
Title: A combination of 2 rapid immunoassays significantly improves diagnostic sensitivity for heparin-induced thrombocytopenia
Description:
Abstract
Objectives
To evaluate the diagnostic performance of chemiluminescent immunoassay (CLIA), latex immunoturbidimetric assay (LIA), and the combination of CLIA/LIA with respect to the functional heparin-induced platelet aggregation (HIPA) test.
Methods
An observational retrospective study was conducted on 100 patients.
All samples were initially tested with CLIA on the ACL TOP AcuStar, and then we performed LIA and CLIA tests concurrently (on the same samples on the ACL TOP 970 CL) and the HIPA test.
Results
The CLIA test was performed on both the AcuStar and the ACL TOP 970 CL, and results were concordant: 68% of patients were negative, and 32% were positive.
The HIPA test confirmed a diagnosis in 26 of 32 and identified 6 false-positive patients and 1 false-negative patient.
The LIA test was performed on the ACL TOP 970 CL: 64% of patients were negative, and the remaining 36% were positive.
The HIPA test confirmed a diagnosis in 24 patients and identified 12 false-positive and 3 false-negative patients.
The combination of CLIA and LIA tests allowed us to categorize 27 true-positive, 13 false-positive, 0 false-negative, and 60 true-negative patients.
Conclusions
The combination of CLIA/LIA provides high sensitivity with a progressively greater probability of detecting platelet-activating antibodies with a higher assay reactivity, reaching 100% when both automated assays yield moderate or strong results.
Related Results
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Abstract
Introduction
Among the most frequently used anticoagulants in hematological testing are tetra-acetic acid (EDTA), sodium citrate, and sodium heparin. However, there is a n...
Case Report: Maggots' Infestation As a Predisposing Condition for Heparin-Induced Thrombocytopenia, a Newest Entity
Case Report: Maggots' Infestation As a Predisposing Condition for Heparin-Induced Thrombocytopenia, a Newest Entity
Abstract
Introduction
Thromobocytopenia is a well-recognized complication of heparin with risk of venous or arterial thrombosis. Heparin induced throm...
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Abstract
The immune response to platelet factor 4 (PF4)/heparin complexes is a frequent iatrogenic complication of heparin therapy associated with development of hep...
Tracing Hematological Shifts in Pregnancy: How Anemia and Thrombocytopenia Evolve Across Trimesters
Tracing Hematological Shifts in Pregnancy: How Anemia and Thrombocytopenia Evolve Across Trimesters
Abstract
Introduction
Given pregnancy's significant impact on hematological parameters, monitoring these changes across trimesters is crucial. This study aims to evaluate hematolog...
HEPARIN BINDING TO HUMAN MONOCYTES: MODULATION BY HISTIDINE-RICH GLYCOPROTEIN
HEPARIN BINDING TO HUMAN MONOCYTES: MODULATION BY HISTIDINE-RICH GLYCOPROTEIN
Heparin and its related glycosaminoglycans interact with a variety of cell types and, irrespective of their anticoagulant activities, have a complex and biologically important infl...
Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions
Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions
Background
Percutaneous peripheral arterial intervention (PPAI) patients are at a high risk of developing heparin-induced thrombocytopenia due to the need for r...
HEPARIN STIMULATES FIBROBLAST GROWTH INDUCED BY PDGF
HEPARIN STIMULATES FIBROBLAST GROWTH INDUCED BY PDGF
Heparin binds to smooth muscle cells and endothelial cells. It inhibits the proliferation of the smooth muscle cells and modulates the growth of endothelial cells. Fibroblasts whic...
Thrombocytopenia in post Covid era: puzzle in the diagnosis.
Thrombocytopenia in post Covid era: puzzle in the diagnosis.
World Health Organization declared the outbreak of coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020, researchers and clinicians have worked diligently to learn ever...

